停經後骨質疏鬆症市場：依藥物類別、給藥途徑、銷售管道及地區分類

Postmenopausal Osteoporosis Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年03月16日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年停經後骨質疏鬆症市場規模為54.132億美元，預計到2033年將達到74.16億美元。預計2026年至2033年，該市場將以4.6%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	54.132億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	4.60%	2033年市場規模預測：	74.16億美元

骨質疏鬆症是一種以骨量和骨骼密度下降為特徵的疾病，導致骨骼脆弱易碎，容易發生骨折。全球範圍內，50歲以上的女性中，每三人就有一人面臨骨質疏鬆症的風險。可能的病因包括荷爾蒙變化以及鈣和維生素D缺乏。除了增加停經後女性骨折的風險外，骨質疏鬆症通常還會導致身體機能下降，並增加發病率和死亡率。女性罹患此病及相關骨質流失的主要原因是雌激素缺乏。其他重要的風險因素包括遺傳、高齡、體重過輕、吸煙和酗酒。攝取充足的蛋白質、鈣和維生素D有助於預防停經後骨質疏鬆症，無需藥物治療。醫生也建議定期鍛煉，並避免吸煙和飲酒，以降低患病風險。對於閉經婦女（自然接近閉經的婦女）以及骨骼密度低或有其他風險因素的婦女，建議使用雌激素或藥物來提高骨骼密度和骨強度。

市場動態

預計在預測期內，非內生性成長活動的增加，例如市場相關人員之間的協議，將推動全球停經後骨質疏鬆症市場的成長。例如，2022年6月10日，全球專業製藥公司Theramex UK Ltd宣布，已與生物技術公司Enzene Biosciences Limited達成許可和供應協議，共同註冊和商業化用於治療骨質疏鬆症的抗吸收藥物地諾Denosumab。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數對全球停經後骨質疏鬆症市場的主要參與者進行了分析：公司亮點、產品系列、關鍵亮點、財務績效和策略。
本報告中的見解將使企業負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球停經後骨質疏鬆症市場報告的目標受眾是該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球停經後骨質疏鬆症市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

Pfizer Inc.
F. Hoffmann-La Roche Ltd
Mylan NV（Viatris Inc.）
Fresenius Kabi AG
Hikma Pharmaceuticals PLC
Novartis AG
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Sun Pharmaceutical Industries Ltd
Ligand Pharmaceuticals Incorporated
Paras Biopharmaceuticals Finland Oy
Eli Lilly and Company
TRANSCENTA HOLDING
Amgen
Gedeon Richter Plc.
Enzene Biosciences
Samsung BioepisL Radius Health, Inc.
Alvotech
AryoGen Pharmed

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI5479

Postmenopausal Osteoporosis Market is estimated to be valued at USD 5,413.2 Mn in 2026 and is expected to reach USD 7,416.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 5,413.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.60%	2033 Value Projection:	USD 7,416 Mn

Osteoporosis is a medical condition in which the bones become brittle and fragile due to decreased bone mass and bone mineral density, leading to frequent fragility fractures. Worldwide, one in three women over the age of 50 is at risk of developing osteoporosis. It could be due to hormonal changes or a lack of calcium and vitamin D. Along with increased incidences of fractures in older, postmenopausal women, osteoporosis may often lead to mobility loss and perhaps morbidity and death. A major reason for developing this disease and the associated bone loss in women is estrogen deficiency. Other important risk factors are genetics, advanced age, being underweight, smoking, alcohol abuse, etc. Ample intake of protein, calcium, and vitamin D may help prevent postmenopausal osteoporosis without pharmacologic means. Doctors also suggest regular physical activity and avoiding smoking and alcohol consumption to lower the risk. For premenopausal women (women naturally approaching menopause) and those with low bone density and other risk factors, estrogen and drugs are recommended for improved bone density and strength.

Market Dynamics

Increasing inorganic growth activities such as agreements among market players is expected to drive the growth of the global postmenopausal osteoporosis market over the forecast period. For instance, on June 10, 2022, Theramex UK Ltd, a global specialty pharmaceutical company announced a license and supply agreement with Enzene Biosciences Limited, a Biotechnology company for the registration and commercialization of Denosumab, an antiresorptive treatment for osteoporosis.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global postmenopausal osteoporosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc., Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global postmenopausal osteoporosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global postmenopausal osteoporosis market

Market Segmentation

Global Postmenopausal Osteoporosis Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
Bisphosphonates
Selective Estrogen Receptor Modulators (SERMs)
RANK Ligand Inhibitors
Anabolic Class
Calcium Metabolism Modifiers
Others (Calcitonin, Denosumab, among Others)
Global Postmenopausal Osteoporosis Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Intravenous Route
Subcutaneous
Global Postmenopausal Osteoporosis Market By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Postmenopausal Osteoporosis Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country
  - U.S.
  - Canada
Latin America
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Country/Region
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Mylan N.V. (Viatris Inc.)
Fresenius Kabi AG
Hikma Pharmaceuticals PLC
Novartis AG
Teva Pharmaceutical Industries Ltd
GlaxoSmithKline plc
Sun Pharmaceutical Industries Ltd
Ligand Pharmaceuticals Incorporated
Paras Biopharmaceuticals Finland Oy
Eli Lilly and Company
TRANSCENTA HOLDING
Amgen
Gedeon Richter Plc.
Enzene Biosciences
Samsung BioepisL Radius Health, Inc.
Alvotech
AryoGen Pharmed

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
Product Launches
Merger, Acquisition, Collaboration
Regulatory Guideline and Compliances
Key Developments
PEST Analysis
Technology Landscape
PORTER's Analysis
Pricing Analysis (2022)

4. Global Postmenopausal Osteoporosis Market, By Drug Class, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Bisphosphonates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Selective Estrogen Receptor Modulators (SERMs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
RANK Ligand Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Anabolic Class
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Calcium Metabolism Modifiers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Others (Calcitonin, Denosumab, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

5. Global Postmenopausal Osteoporosis Market, By Route of Administration, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Intravenous Route
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Global Postmenopausal Osteoporosis Market, By Distribution Channel, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segments Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

7. Global Postmenopausal Osteoporosis Market, By Region, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mylan N.V. (Viatris Inc.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ligand Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Paras Biopharmaceuticals Finland Oy
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
TRANSCENTA HOLDING
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gedeon Richter Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Enzene Biosciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Samsung BioepisL Radius Health, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Alvotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AryoGen Pharmed
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies